Proteomic analysis of soft tissue tumor implants treated with a novel polybisphosphonate

Cancer Genomics and Proteomics

Volumn 11, Issue 1, 2014, Pages 39-50

  Alaiya, Ayodele ^a   Fox, Jonathan ^b   Bobis, Steve ^a   Matic, Goran ^a   Shinwari, Zakia ^a   Barhoush, Eman ^a   Márquez, Marcela ^c   Nilsson, Sten ^c   Holmberg, Anders R ^c  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Waters UK   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Breast cancer; Osteodex; Proteomic analysis; Soft tissue; Tumor implants

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; OSTEODEX; POLYPHOSPHATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRAFT; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GENERAL CONDITION; LIQUID CHROMATOGRAPHY; MOUSE; MULTIPLE CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEOMICS; SINGLE DRUG DOSE; SOFT TISSUE TUMOR; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE COURSE; DRUG SCREENING; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; MICE; MICE, NUDE; PROTEOMICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901386594     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Buijs JT and van der Pluijm G: Osteotropic cancers: from primary tumor to bone. Cancer letters 273: 177-193, 2009.
2. Bussard KM, Gay CV, and Mastro AM: The bone microenvironment in metastasis; what is special about bone? Cancer metastasis reviews 27 : 41-55, 2008.
3. Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer metastasis reviews 8: 98-101, 1989.
4. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human pathology 31: 578-583, 2000. (Pubitemid 30323983)
5. Datta K, Muders M, Zhang H and Tindall DJ: Mechanism of lymph node metastasis in prostate cancer. Future oncology 6: 823-836, 2010.
6. Elias D and Di Pietroantonio D: Surgery for liver metastases from breast cancer. HPB: the official journal of the International Hepato Pancreato Biliary Association 8 : 97-99, 2006.
7. Jatoi I, Hilsenbeck SG, Clark GM and Osborne CK: Significance of axillary lymph node metastasis in primary breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17: 2334-2340, 1999.
8. Long MA and Husband JE: Features of unusual metastases from prostate cancer. The British journal of radiology 72: 933-941, 1999. (Pubitemid 29484354)
9. Roche H and Vahdat LT: Treatment of metastatic breast cancer: second line and beyond. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 22 : 1000-1010, 2011.
10. Tkaczuk KH: Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clinical therapeutics 31 Pt 2: 2273-2289, 2009.
11. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, and Sawyers CL: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 : 787-790, 2009.
12. Daubine F, R LEB, Marquez M, Nilsson S, Schroder T and Holmberg AR: Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate. Anticancer Res 31: 4141-4145, 2011.
13. Holmberg AR, Lerner UH, Alayia AA, Al-Mohanna M, Adra C, Marquez M, Meurling L and Nilsson S: Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis. International journal of oncology 37: 563-567, 2010.
14. Greish K: Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods in molecular biology 624 : 25-37, 2010.
15. Alaiya AA, Franzen B, Moberger B, Silfversward C, Linder S and Auer G: Two-dimensional gel analysis of protein expression in ovarian tumors shows a low degree of intratumoral heterogeneity. Electrophoresis 20 : 1039-1046, 1999. (Pubitemid 29222466)
16. Franzen B, Auer G, Alaiya AA, Eriksson E, Uryu K, Hirano T, Okuzawa K, Kato H and Linder S: Assessment of homogeneity in polypeptide expression in breast carcinomas shows widely variable expression in highly malignant tumors. International journal of cancer Journal international du cancer 69: 408-414, 1996.
17. Li GZ, Vissers JP, Silva JC, Golick D, Gorenstein MV and Geromanos SJ: Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics 9: 1696-1719, 2009.
18. Ueno T, Toi M, and Linder S: Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomedicine & pharmacotherapy= Biomedecine & pharmacotherapie 59 Suppl 2: S359-362, 2005.
19. Alaiya A, Al-Mohanna M, and Linder S: Clinical cancer proteomics: promises and pitfalls. Journal of proteome research 4: 1213-1222, 2005. (Pubitemid 41213336)
20. Linder S and Alaiya A: Serum efficacy biomarkers for oncology. Biomarkers in medicine 3 : 47-54, 2009.
21. Chavanas S, Mechin MC, Takahara H, Kawada A, Nachat R, Serre G and Simon M: Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 330: 19-27, 2004. (Pubitemid 38490414)
22. Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez-Jimenez E, Leton R, Cascon A, Robledo M and Rodriguez-Antona C: Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton 67: 214-223, 2010.
23. Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S and Ferlini C: Gender influences the class III and V beta-tubulin ability to predict poor outcome in colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 18: 2964-2975, 2012.
24. Nicholls C, Pinto AR, Li H, Li L, Wang L, Simpson R and Liu JP: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component. Proceedings of the National Academy of Sciences of the United States of America 109: 13308-13313, 2012.
25. Cui WJ, Liu Y, Zhou XL, Wang FZ, Zhang XD and Ye LH: Myosin light chain kinase is responsible for high proliferative ability of breast cancer cells via anti-apoptosis involving p38 pathway. Acta pharmacologica Sinica 31 : 725-732, 2010.